ETF Managers Group LLC Increases Position in DexCom, Inc. (DXCM)

ETF Managers Group LLC boosted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 8.5% in the first quarter, Holdings Channel reports. The institutional investor owned 1,929 shares of the medical device company’s stock after acquiring an additional 151 shares during the period. ETF Managers Group LLC’s holdings in DexCom were worth $230,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc boosted its stake in DexCom by 11.5% during the third quarter. Vanguard Group Inc now owns 7,942,861 shares of the medical device company’s stock valued at $1,136,147,000 after buying an additional 816,247 shares during the last quarter. Janus Henderson Group PLC boosted its stake in DexCom by 16.5% during the first quarter. Janus Henderson Group PLC now owns 1,452,485 shares of the medical device company’s stock valued at $172,992,000 after buying an additional 205,402 shares during the last quarter. Geode Capital Management LLC boosted its stake in DexCom by 17.2% during the fourth quarter. Geode Capital Management LLC now owns 1,042,131 shares of the medical device company’s stock valued at $124,776,000 after buying an additional 152,781 shares during the last quarter. Norges Bank bought a new position in DexCom during the fourth quarter valued at approximately $107,191,000. Finally, Mackenzie Financial Corp boosted its stake in DexCom by 13.7% during the fourth quarter. Mackenzie Financial Corp now owns 767,971 shares of the medical device company’s stock valued at $92,003,000 after buying an additional 92,289 shares during the last quarter.

NASDAQ:DXCM opened at $118.75 on Thursday. The company has a market capitalization of $10.80 billion, a PE ratio of 211.77 and a beta of 0.73. DexCom, Inc. has a 1 year low of $85.76 and a 1 year high of $156.16. The company has a debt-to-equity ratio of 1.57, a current ratio of 7.18 and a quick ratio of 6.75.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Wednesday, May 1st. The medical device company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.12. The business had revenue of $280.50 million during the quarter, compared to analyst estimates of $246.10 million. DexCom had a positive return on equity of 8.45% and a negative net margin of 11.51%. The company’s revenue for the quarter was up 52.1% on a year-over-year basis. During the same period last year, the company earned ($0.30) EPS. Research analysts expect that DexCom, Inc. will post 0.77 EPS for the current fiscal year.

In other news, SVP Patrick Michael Murphy sold 400 shares of the stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $141.56, for a total value of $56,624.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Andrew K. Balo sold 10,917 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $142.79, for a total value of $1,558,838.43. The disclosure for this sale can be found here. Over the last quarter, insiders sold 96,530 shares of company stock worth $13,231,236. Company insiders own 1.80% of the company’s stock.

A number of equities analysts recently commented on DXCM shares. TheStreet lowered DexCom from a “c” rating to a “d+” rating in a research note on Friday, April 5th. Raymond James lowered their price objective on DexCom from $160.00 to $150.00 and set an “outperform” rating for the company in a research note on Thursday, May 2nd. Cowen raised their price objective on DexCom from $150.00 to $175.00 and gave the company an “outperform” rating in a research note on Friday, February 22nd. Zacks Investment Research raised DexCom from a “hold” rating to a “buy” rating and set a $138.00 price objective for the company in a research note on Monday, May 6th. Finally, Morgan Stanley raised their price objective on DexCom from $135.00 to $160.00 and gave the company an “equal weight” rating in a research note on Monday, February 25th. Five equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. DexCom has an average rating of “Buy” and an average target price of $152.25.

TRADEMARK VIOLATION WARNING: This article was originally reported by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/05/23/etf-managers-group-llc-increases-position-in-dexcom-inc-dxcm.html.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Story: Trading Strategy Methods for Individual Investors

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.